ausbiz speaks with Race CEO on the Phase 1 trial ethics approval

Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial.

Watch the full video via this link.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@raceoncology.com T: +61 2 8051 3043
© 2025 Race Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Race Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.